Phaseline

Companies › Cartography Biosciences

Cartography Biosciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Apr 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CBI-1214
Bispecific T cell engager targeting LY6G6D on colorectal cancer cells and CD3 on T cells
LY6G6D, CD3Phase 1Colorectal CancerApr 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07321106CBI-1214Phase 1Colorectal CancerOncologyApr 2029

Targets

LY6G6D (1) CD3 (1)

Companies with the same targets

Vironexis Biotherapeutics Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai EpimAb Biotherapeutics Kali Therapeutics Johnson & Johnson (Janssen) Excyte Biopharma OncoC4 Lakefront Biotherapeutics West Antengene Biologics AstraZeneca

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.